GAITHERSBURG, Md. and SHANGHAI, June 23, 2022 /PRNewswire/ — I-Mab (“I-Mab” or the “Firm”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical firm dedicated to the invention, improvement, and commercialization of novel biologics, at this time introduced that it was ranked among the many high firms in 5 totally different classes by main world monetary publication Institutional Investor, primarily based on its 2022 All-Asia Govt Crew survey. The awards acknowledge I-Mab’s continued robust management, company governance, ESG technique, and investor relations capabilities.
I-Mab was acknowledged within the “Honored Firms,” “Finest CEO,” “Finest CFO,” “Finest IR Skilled,” “Finest IR Program,” and “Finest ESG” classes. That is additionally the second consecutive 12 months that I-Mab has been named because the “Honored Firm” inside the healthcare and prescribed drugs sector. With its globally aggressive pipeline of novel or extremely differentiated biologics advancing in medical improvement, I-Mab has demonstrated its dedication to innovation and worth creation for shareholders. The rating by Institutional Investor signifies capital market recognition of the Firm’s continued management in innovation and excellence in company governance.
The small print of I-Mab’s rankings are:
- The Firm is known as the “the Honored Firm” in Core Asia, Mainland China and Small & Midcap outcomes.
- Dr. Jingwu Zang is known as “Finest CEO” and ranked high 3 in Mainland China sell-side, Small & Midcap total and sell-side outcomes.
- Mr. John Lengthy is known as “Finest CFO” and ranked high 3 in Core Asia sell-side, Mainland China sell-side, Small & Midcap total, buy-side and sell-side outcomes.
- Mr. Tianyi Zhang is known as “Finest IR Skilled” and ranked high 3 in Small & Midcap sell-side outcomes.
- The Firm’s IR crew is known as “Finest IR Program” and ranked high 3 in Mainland China sell-side, Small & Midcap total and sell-side outcomes.
- The Firm’s ESG program is acknowledged as high 3 “Finest ESG” in Core Asia sell-side, Mainland China sell-side, Small & Midcap total and sell-side outcomes.
Institutional Investor is likely one of the business’s most trusted world sources for analysis and rankings amongst high analysts and portfolio managers whereas persevering with to set the usual by which excellence is measured. Institutional Investor’s “2022 All-Asia Govt Crew” survey outcomes replicate the opinions of 4,854 traders, portfolio managers, and analysts from 670 monetary providers corporations globally, nominating a complete of 1,612 firms and a pair of,606 people throughout 18 sectors.
I-Mab (Nasdaq: IMAB) is an innovation-driven world biopharma firm targeted on the invention, improvement and commercialization of novel and extremely differentiated biologics for immuno-oncology ailments. The Firm’s mission is to convey transformational medicines to sufferers all over the world by means of innovation. I-Mab’s globally aggressive pipeline of greater than 20 medical and preclinical-stage drug candidates is pushed by its inner discovery and world partnerships for in-licensing, primarily based on the Firm’s Quick-to-Proof-of-Idea and Quick-to-Market improvement methods. The Firm is progressing from a clinical-stage biotech firm into an modern world specialty biopharmaceutical firm with cutting-edge R&D capabilities, a world-class GMP manufacturing facility, and business functionality. I-Mab has established its world footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the US. For extra info, please go to http://www.i-mabbiopharma.com and comply with I-Mab on LinkedIn, Twitter, and WeChat.
Ahead Wanting Statements
This press launch contains sure disclosures which comprise “forward-looking statements.” You’ll be able to determine forward-looking statements as a result of they comprise phrases similar to “anticipate” and “anticipated.” Ahead-looking statements are primarily based on I-Mab’s present expectations and assumptions. As a result of forward-looking statements relate to the long run, they’re topic to inherent uncertainties, dangers and modifications in circumstances that will differ materially from these contemplated by the forward-looking statements, that are neither statements of historic reality nor ensures or assurances of future efficiency. Vital components that might trigger precise outcomes to vary materially from these within the forward-looking statements are set forth in filings with the U.S. Securities and Trade Fee. I-Mab undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not because of new info, future occasions or in any other case, besides as could also be required by legislation.
View authentic content material to obtain multimedia:https://www.prnewswire.com/news-releases/i-mab-receives-top-rankings-in-five-categories-by-institutional-investor-301573977.html